EGFR and non-small cell lung carcinoma: First-generation EGFR-TKIs combined with bevacizumab or ramucirumab resulted in significantly longer median PFS than EGFR-TKI monotherapy (16–19 months vs. 9–13 months) in untreated patients with advanced-stage EGFR-mutant NSCLC harboring either the exon 19 deletion or the L858R mutation in a phase II/III trial [13–15].